Changes to the Code
H.R. 8630 · PEAT Act of 2026 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 262 Regulation of biological products
3 changes the bill asks for here, 2 carried out
- Carried out:
by striking The term and inserting the following:(A) The term; and
- Carried out:
by adding at the end the following:
(B) A biologic described in subparagraph (A) may not be treated as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic..
- Not carried out:
Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended in subparagraph (A), as designated by subsection (a)(1), by striking
protein ,
and insertingprotein,
.“protein ,” isn't in § 262(i)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“protein ,” not found in /us/usc/t42/s262/i/1/A
§ 262(i)“Biological product” defined(1)–(2)
Start of § 262 to (h) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (i) | (i) “Biological product” defined | (i) “Biological product” defined | ||
| In this section: | In this section: | |||
| (1) | (1) | (1) | ||
| (1)(A) | (A) [inserted: ] | |||
| [inserted: The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.] | ||||
| (1)(B) | (B) [inserted: ] | |||
| [inserted: A biologic described in subparagraph (A) may not be treated as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic.] | ||||
| (1) | ||||
| (2) | (2) | (2) | ||
| The term “biosimilar” or “biosimilarity”, in reference to a biological product that is the subject of an application under subsection (k), means— | The term “biosimilar” or “biosimilarity”, in reference to a biological product that is the subject of an application under subsection (k), means— | |||
| (2)(A) | (A) | (A) | ||
| that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and | that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and | |||
Rest of § 262 unchanged